U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H5O7.Cr
Molecular Weight 241.0961
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHROMIC CITRATE

SMILES

C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Cr+3]

InChI

InChIKey=SWXXYWDHQDTFSU-UHFFFAOYSA-K
InChI=1S/C6H8O7.Cr/c7-3(8)1-6(13,5(11)12)2-4(9)10;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);/q;+3/p-3

HIDE SMILES / InChI

Molecular Formula C6H5O7
Molecular Weight 189.1
Charge -3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Cr
Molecular Weight 51.9961
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Chromium sulfate(III) hexahydrate or chromium sulphate, a trivalent compound of chromium that was investigated as a toxic compound. Experiments on rodent have shown chromium sulfate produced severe and widespread effects in the nasal cavity, larynx, lungs, and mediastinal lymph node. Effects were characterized by the accumulation of foreign material, infiltration of alveolar macrophages, septal cell hyperplasia, and granulomatous and chronic inflammation. Besides, chromium sulphate exerted a disadvantageous effect on the skeleton, as it decreases bone density and resistance.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
CHROMIUM

Approved Use

Chromium 4 mcg/mL (Chromic Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition. Administration helps to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.

Launch Date

1.12000316E12
PubMed

PubMed

TitleDatePubMed
Cytokine induction in human epidermal keratinocytes exposed to contact irritants and its relation to chemical-induced inflammation in mouse skin.
1994 Jun
Silicate antibodies in women with silicone breast implants: development of an assay for detection of humoral immunity.
1996 Mar
Activation of MAPKs in human bronchial epithelial cells exposed to metals.
1998 Sep
Thirteen-week subchronic rat inhalation toxicity study with a recovery phase of trivalent chromium compounds, chromic oxide, and basic chromium sulfate.
1999 Dec
Status of antioxidant defense system in chromium-induced Swiss mice tissues.
2004 Jul
The role of oxidative stress in the modulation of aryl hydrocarbon receptor-regulated genes by As3+, Cd2+, and Cr6+.
2005 Dec 1
Transcriptional activation and posttranscriptional modification of Cyp1a1 by arsenite, cadmium, and chromium.
2007 Aug
Effects of subchronic exposure via drinking water to a mixture of eight water-contaminating metals: a biochemical and histopathological study in male rats.
2007 Nov
Immunosuppressive effect of subchronic exposure to a mixture of eight heavy metals, found as groundwater contaminants in different areas of India, through drinking water in male rats.
2007 Oct
The peripheral quantitative computed tomographic and densitometric analysis of skeletal tissue in male Wistar rats after chromium sulfate treatment.
2017 Sep 21
Patents

Patents

Substance Class Chemical
Created
by admin
on Sat Jun 26 02:58:29 UTC 2021
Edited
by admin
on Sat Jun 26 02:58:29 UTC 2021
Record UNII
LQC76G8WUE
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHROMIC CITRATE
Common Name English
CHROMIUM(3+) CITRATE
Systematic Name English
CITRIC ACID, CHROMIUM SALT
Common Name English
CHROMIUM(III) CITRATE
WHO-DD  
Systematic Name English
1,2,3-PROPANETRICARBOXYLIC ACID, 2-HYDROXY-, CHROMIUM(3+) SALT (1:1)
Systematic Name English
CHROMIUM(III) CITRATE [WHO-DD]
Common Name English
1,2,3-PROPANETRICARBOXYLIC ACID, 2-HYDROXY-, CHROMIUM(3+) SALT
Systematic Name English
CHROMIUM CITRATE
Systematic Name English
Code System Code Type Description
PUBCHEM
6453431
Created by admin on Sat Jun 26 02:58:29 UTC 2021 , Edited by admin on Sat Jun 26 02:58:29 UTC 2021
PRIMARY
FDA UNII
LQC76G8WUE
Created by admin on Sat Jun 26 02:58:29 UTC 2021 , Edited by admin on Sat Jun 26 02:58:29 UTC 2021
PRIMARY
EVMPD
SUB130398
Created by admin on Sat Jun 26 02:58:29 UTC 2021 , Edited by admin on Sat Jun 26 02:58:29 UTC 2021
PRIMARY
CAS
57072-40-9
Created by admin on Sat Jun 26 02:58:29 UTC 2021 , Edited by admin on Sat Jun 26 02:58:29 UTC 2021
NON-SPECIFIC STOICHIOMETRY
ECHA (EC/EINECS)
260-543-6
Created by admin on Sat Jun 26 02:58:29 UTC 2021 , Edited by admin on Sat Jun 26 02:58:29 UTC 2021
PRIMARY
DRUG BANK
DB14526
Created by admin on Sat Jun 26 02:58:29 UTC 2021 , Edited by admin on Sat Jun 26 02:58:29 UTC 2021
PRIMARY
EPA CompTox
57072-40-9
Created by admin on Sat Jun 26 02:58:29 UTC 2021 , Edited by admin on Sat Jun 26 02:58:29 UTC 2021
PRIMARY
RXCUI
407906
Created by admin on Sat Jun 26 02:58:29 UTC 2021 , Edited by admin on Sat Jun 26 02:58:29 UTC 2021
PRIMARY RxNorm
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE